Product Information
YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR is a brand biologic product labeled by CELLTRION USA, Inc., priced at $912.2140 per EA under NDC 72606003009. Its NADAC has been published 33 times since Feb 18, 2026.
Manufacturer
CELLTRION USA, Inc.NDC
72606003009
Classification
Brand Biologic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Biologic (BLA)
FDA Application
BLA761219On Market Since
5/23/2023
Price Statistics
The NADAC for YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR has been published 33 times since Feb 18, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $912.2140 per EA |
|---|---|
| All-time high | $913.5967 (Sep 16, 2026) |
| All-time low | $912.2140 (Sep 23, 2026) |
| 52-week high | $913.5967 |
| 52-week low | $912.2140 |
| Median price | $913.5967 |
| Average price | $913.3654 |
| Largest weekly change | -0.2% (Sep 23, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 46% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
CELLTRION USA, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
adalimumab-aaty market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR?
The current National Average Drug Acquisition Cost (NADAC) for YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR, manufactured by CELLTRION USA, Inc., is $912.2140 per EA (NDC 72606003009), effective Sep 30, 2026.
How has the price of YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR changed over time?
Over the history we have for it, the NADAC for YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR has held within roughly two percent of its current level. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR?
Since Feb 18, 2026, the NADAC for YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR has ranged from a low of $912.2140 (Sep 23, 2026) to a high of $913.5967 (Sep 16, 2026), with a median of $913.5967 per EA.
Are there cheaper alternatives to YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR, is $490.0367 per EA — about 46% below YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR.
Who manufactures YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR?
YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR (NDC 72606003009) is labeled by CELLTRION USA, Inc., and CMS classifies it as a brand biologic product.